Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Medical
- Device
- Surgical
- Kidneys
- Diagnostic
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 126813
License Grant
Licensor granted Licensee, a subsidiary, an exclusive North American license for the technology.
License Property
The technology is the processes and know-how for the manufacture of polysulfone dialyzers.
Field of Use
A dialyzer is often referred to as an “artificial kidney.†Its function is to remove the excess wastes and fluid from the blood, when the patient's kidneys can no longer perform that task. Polysulfone dialyzers are preferred because of their superior biocompatibility and lower anticoagulation requirements. The surface of the dialyzer membrane should approximately match the body surface area of the patient.
IPSCIO Record ID: 1614
License Grant
The Licensor, an individual, grants to Licensee the exclusive right to incorporate the Invention into an integrated assembly that also includes a system for hemodialysis; Dialyzer Reuse System (Patent No. 4,695,385).
License Property
This grant is solely for the incorporation of the Invention into an integrated assembly that also includes a hemodialysis system.
Field of Use
The Company is granted solely for the incorporation of the Invention into an integrated assembly that also includes a hemodialysis system.
IPSCIO Record ID: 1613
License Grant
Licensor, an individual, grants to Licensee the worldwide, exclusive right to make, have made, use and sell Licensed Products.
License Property
United States Patent Application No. 07/748,036, filed August 21, 1991 and entitled Artificial Kidney For Frequent (Daily) Hemodialysis.
Field of Use
The Company obtains an exclusive license for Artificial Kidney For Frequent (Daily) Hemodialysis.
IPSCIO Record ID: 308644
License Grant
The Medical School, a significant shareholder of the licensee, granted the Licensee of England (i) an exclusive license, with sub-license rights, to use certain patent rights covering specific inventions concerning the utilization of biomarkers guided artificial intelligence techniques for detecting kidney functional decline (the Technology), (ii) a non-exclusive license under unregistered licensed copyrights and licensed know-how and (iii) an exclusive option to obtain licensed technology conceived after May 30, 2018.
License Property
Biomarkers are typically genes or proteins that indicate the existence and severity of certain conditions (such as kidney disease) and can be measured from a simple blood sample.
FractalDx, a technology portfolio of diagnostic and prognostic products. The FractalDx technology is based principally on sequencing biomarkers from a patient’s blood using widely available instrument platforms. Two products have been developed from the portfolio a prognostic test performed prior to kidney transplant to predict which transplant recipients are most at risk of acute rejection and a diagnostic test for evidence of rejection of the transplanted kidney in advance of any clinical symptoms.
Licensor is a pioneer company in kidney health and devoted to discovering causes, prevention and treatment of kidney disorders.
Field of Use
The field of use relating to sequencing biomarkers from a patients blood for diagnostic testing prior to kidney transplant to predict rejection.
Licensee is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
